Retail chatter around Cogent Biosciences surged on Tuesday as multiple firms raised their price targets following strong ...

Cogent Biosciences, Inc. is a Strong Buy after trial data for bezuclastinib & market growth potential in systemic ...

Cogent Biosciences (NASDAQ:COGT) has announced the pricing of its previously disclosed underwritten public offering of 22,222,223 shares of its common stock at $9.00 per share, for expected gross ...

Cogent Biosciences is based in Waltham, MA and Boulder, CO. Forward-looking Statements This press release contains forward-looking statements within the meaning of the Private Securities ...

Cogent Biosciences said its experimental drug reduced the symptoms of a chronic immune disorder called indolent systemic ...

Cogent Biosciences surges 31% on positive data for bezuclastinib in treating systemic mastocytosis. Read more here.

Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically ...

Cogent reported positive SUMMIT trial data for bezuclastinib in NonAdvSM and plans to file for FDA approval by late 2025.

A phase 3 trial of Cogent Biosciences’ bezuclastinib has hit its primary endpoint, teeing the biotech up to seek FDA approval ...

Shares of Cogent Biosciences were higher after the company disclosed what it called positive top-line results from a recent trial of its treatment for certain types of mastocytosis, a rare disorder in ...

Shares of Cogent Biosciences were trading in the red in Tuesday's after-hours market, following news the biotechnology company commenced an underwritten public offering for $150 million of its common ...